|Phone||47 22 95 81 93|
|Grant, 11/2012 |
Norwegian Research Council
|Seed, 6/2013 ||€733k|
Vaccibody AS was established 2007 as a spin-off from the University of Oslo and Oslo University hospital. The Vaccibody technology was conceived in the laboratory of Professor Bjarne Bogen, one of Europe’s leading immunologists. With Professor Inger Sandlie and Agnete Fredriksen he invented the basic construct of a novel vaccine molecule, and impressive preclinical results in animal studies was demonstrated. All rights to the technology was assigned to Vaccibody at the company establishment.
With funding from The Norwegian Research Council , Innovation Norway, and private investors, the company has established the proof of concept for the vaccine platform. Vaccibody has now started the development of an immuntherapy against HPV-induced malignancies, such as precanceous lesions of cervical cancer.